Vertex Telaprevir NDA In Treatment-Naive Hep C Now Planned For 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex Pharmaceuticals expects to have data available from Phase III trials evaluating the protease inhibitor telaprevir in patients with hepatitis C by mid-2010, the company announced Jan. 23. The program was initiated in March